



GENOMICS | GENETICS | R&D | DIAGNOSTIC TESTS

Genomic Vision: convening of another Extraordinary General Meeting on October 30, 2020

Bagneux (France) - Genomic Vision (the “Company” - FR0011799907 – GV), a company specialized in the development of in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), informs its shareholders that, contrary to what was previously indicated in its press release of August 10, 2020, the thirty second resolution on the implementation of the financing line agreed with Winance¹ was not validly adopted despite the unanimous support of shareholders who voted, insofar as the required quorum for this specific resolution was not met.

Within this context, the Company has decided to convene another Extraordinary General Meeting, on October 30, 2020 at 10 am CEST, behind closed doors, whose agenda will be the adoption of this resolution. The Company has asked the Nanterre Commercial Court to appoint a special purpose trustee to represent the shareholders unable to attend the Meeting, and thus ensure that the required quorum is met.

In compliance with current legislation and the recommendations of the AMF French stock market authority, Genomic Vision’s shareholders are invited to exclusively express their vote remotely, before the EGM, either via a postal vote or by granting proxy to the Chairman of the Emergency General Meeting, in accordance with the arrangements indicated in the Company’s notice of meeting that will be published in the BALO official bulletin of legal announcements on September 25, 2020.

All the preparatory documents are available from the Company on request and are also available on the Company’s website (in the General Assembly subsection of the Investors section).

For further information on the financing line via the reserved issuance of bonds convertible into ordinary shares to which a share subscription warrant is attached (the warrants and, together with the shares to which they are attached, the equity subscription warrants or “ABSA” and, with the convertible notes, the convertible notes with equity warrants or “OCABSA”) in favor of Winance, please refer to the Company’s press release of June 15, 2020.

For guidance purposes, and based on Genomic Vision’s share price of €0.34 on September 21, 2020, the conversion of all the notes (representing total financing of €12 million) and the exercise of all the

¹ As a reminder, that resolution asked the Shareholders’ Meeting to grant the Board of Directors the power to undertake a capital increase via the issuance of convertible notes with warrants (OCABSA) with shareholders’ preemptive rights waived in favor of Winance within the framework of a convertible bond financing line for a nominal amount of €12 million in 12 equal tranches.

warrants would result in the issuance of a total of 51,724,137 new ordinary shares. A shareholder currently holding 1% of the Company's share capital would then hold 0.48% of its share capital.

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext's regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com

CONTACTS

Genomic Vision

Dominique Rémy-Renou

CEO

Tel.: +33 1 49 08 07 51

investisseurs@genomicvision.com

Ulysse Communication

Press Relations

Bruno Arabian

Tel.: +33 1 42 68 29 70

[barabian@ulyse-](mailto:barabian@ulyse-communication.com)

communication.com

NewCap

Investor Relations

& Strategic Communications

Tel.: +33 1 44 71 94 94

gv@newcap.eu



Member of the CAC[®] Mid & Small and CAC[®] All-Tradable indexes

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the "Risk Factors" section of the reference document dated March 29, 2019 filed with the AMF under reference number R19-004, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.